Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase

doi:10.1002/ajh.26943

. 2023 Jul;98(7):E183-E186.

doi: 10.1002/ajh.26943. Epub 2023 May 2.

Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase

Sen Yang¹, Xiaoshuai Zhang¹, Robert Peter Gale², Xin Du³, Chun-Yan Chen⁴, Jian-Yu Weng⁵, Jian Huang^{6

7}, Fei Li⁸, Yun Zeng⁹, Zhen Xiao¹⁰, Jian-da Hu¹¹, Li-Jie Yang¹², Zhuo-Gang Liu¹³, Guo-Hui Li¹², Xiu-Li Sun¹⁴, Wei Yang¹³, Ru Feng¹⁵, Yan-Qiu Han¹⁰, Yu Jing¹⁶, Na Xu¹⁷, Xiao-Li Liu¹⁷, Zhen-Fang Liu¹⁸, Xiao-Dong Wang^{19

20

21}, Shi-Xin Wu²², Rong Liang²³, Yan-Li Zhang²⁴, Yun-Fan Yang²⁵, Huan-Ling Zhu²⁵, Ling Pan²⁵, Li Meng²⁶, Yan-Hong Zhao²⁷, Hai Yi²⁸, Yi-Lan Liu²⁸, Wei-Hua Zhang²⁹, Yuan-Jun Zheng²⁹, Ze-Ping Zhou³⁰, Su-Ning Chen³¹, Hui-Ying Qiu³¹, Wei-Ming Li³², Zhi-Lin Jia¹⁴, Yan-Liang Bai³³, Li-E Lin³⁴, Bing-Cheng Liu³⁵, Chun-Shui Liu³⁶, Jian-Min Luo³⁷, Jun-Xia Meng³⁸, Zhi-Qiang Sun³⁹, Yan-Qing Zhang⁴⁰, Xiao-Jun Huang^{1

41

42

43}, Qian Jiang^{1

41}

Affiliations

¹ National Clinical Research Center for Haematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
² Centre for Haematology, Department of Immunology and Inflammation, Imperial College of Science, Technology and Medicine, London, UK.
³ Department of Hematology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China.
⁴ Department of Haematology, Qilu Hospital, Shandong University, Jinan, China.
⁵ Department of Haematology, Guangdong Provincial People's Hospital, Guangzhou, China.
⁶ Department of Haematology, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu, China.
⁷ Department of Haematology, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
⁸ Center of Haematology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
⁹ The First Affiliated Hospital of Kunming Medical University, Kunming, China.
¹⁰ The Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia, China.
¹¹ Fujian Medical University Union Hospital, Fuzhou, China.
¹² Xi'an International Medical Center Hospital, Xi'an, China.
¹³ Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, China.
¹⁴ Department of Hematology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
¹⁵ Department of Hematology, Beijing Hospital, Beijing, China.
¹⁶ Department of Hematology, Chinese People's Liberation Army General Hospital, Beijing, China.
¹⁷ Department of Haematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
¹⁸ Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
¹⁹ Department of Haematology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
²⁰ Department of Haematology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, China.
²¹ Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China.
²² The Second Affiliated Hospital of Fujian Medical University, Fujian, China.
²³ Department of Haematology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
²⁴ Department of Haematology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
²⁵ Department of Haematology, Institute of Haematology, West China Hospital, Sichuan University, Chengdu, China.
²⁶ Department of Haematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
²⁷ The First Affiliated Hospital, Harbin Medical University, Harbin, China.
²⁸ Hematology Department, The General Hospital of Western Theater Command, PLA, Chengdu, China.
²⁹ First Hospital of Shangxi Medical University, Shangxi, China.
³⁰ Dept. of Hematology, The Second Hospital Affiliated to Kunming medical university, Kunming, China.
³¹ National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation of Soochow University, Suzhou, China.
³² Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
³³ Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, China.
³⁴ Hainan General Hospital, Hainan, China.
³⁵ National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
³⁶ First Hospital of Jilin University, Jilin, China.
³⁷ The Second Hospital of Hebei Medical University, Shijiazhuang, China.
³⁸ Anyang District Hospital, Puyang, China.
³⁹ Shenzhen Hospital of Southern Medical University, Shenzhen, China.
⁴⁰ Department of Hematology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
⁴¹ Collaborative Innovation Center of Haematology, Soochow University, Suzhou, China.
⁴² Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China.
⁴³ Research Unit of Key Technique for Diagnosis and Treatments of Haematologic Malignancies, Chinese Academy of Medical Sciences, Beijing, China.

PMID: 37128776
DOI: 10.1002/ajh.26943

Free article

Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase

Sen Yang et al. Am J Hematol. 2023 Jul.

Free article

. 2023 Jul;98(7):E183-E186.

doi: 10.1002/ajh.26943. Epub 2023 May 2.

Authors

Affiliations

¹ National Clinical Research Center for Haematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
² Centre for Haematology, Department of Immunology and Inflammation, Imperial College of Science, Technology and Medicine, London, UK.
³ Department of Hematology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China.
⁴ Department of Haematology, Qilu Hospital, Shandong University, Jinan, China.
⁵ Department of Haematology, Guangdong Provincial People's Hospital, Guangzhou, China.
⁶ Department of Haematology, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu, China.
⁷ Department of Haematology, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
⁸ Center of Haematology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
⁹ The First Affiliated Hospital of Kunming Medical University, Kunming, China.
¹⁰ The Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia, China.
¹¹ Fujian Medical University Union Hospital, Fuzhou, China.
¹² Xi'an International Medical Center Hospital, Xi'an, China.
¹³ Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, China.
¹⁴ Department of Hematology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
¹⁵ Department of Hematology, Beijing Hospital, Beijing, China.
¹⁶ Department of Hematology, Chinese People's Liberation Army General Hospital, Beijing, China.
¹⁷ Department of Haematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
¹⁸ Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
¹⁹ Department of Haematology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
²⁰ Department of Haematology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, China.
²¹ Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China.
²² The Second Affiliated Hospital of Fujian Medical University, Fujian, China.
²³ Department of Haematology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
²⁴ Department of Haematology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
²⁵ Department of Haematology, Institute of Haematology, West China Hospital, Sichuan University, Chengdu, China.
²⁶ Department of Haematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
²⁷ The First Affiliated Hospital, Harbin Medical University, Harbin, China.
²⁸ Hematology Department, The General Hospital of Western Theater Command, PLA, Chengdu, China.
²⁹ First Hospital of Shangxi Medical University, Shangxi, China.
³⁰ Dept. of Hematology, The Second Hospital Affiliated to Kunming medical university, Kunming, China.
³¹ National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation of Soochow University, Suzhou, China.
³² Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
³³ Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, China.
³⁴ Hainan General Hospital, Hainan, China.
³⁵ National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
³⁶ First Hospital of Jilin University, Jilin, China.
³⁷ The Second Hospital of Hebei Medical University, Shijiazhuang, China.
³⁸ Anyang District Hospital, Puyang, China.
³⁹ Shenzhen Hospital of Southern Medical University, Shenzhen, China.
⁴⁰ Department of Hematology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
⁴¹ Collaborative Innovation Center of Haematology, Soochow University, Suzhou, China.
⁴² Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China.
⁴³ Research Unit of Key Technique for Diagnosis and Treatments of Haematologic Malignancies, Chinese Academy of Medical Sciences, Beijing, China.

PMID: 37128776
DOI: 10.1002/ajh.26943

No abstract available

PubMed Disclaimer

References

REFERENCES

1. Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966-984.
1. Ohanian M, Kantarjian HM, Shoukier M, et al. The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia. Am J Hematol. 2020;95:1127-1134.
1. Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol. 2004;57(12):1288-1294.
1. Mnatzaganian G, Davidson DC, Hiller JE, Ryan P. Propensity score matching and randomization. J Clin Epidemiol. 2015;68(7):760-768.
1. Graham R, Mancher M, Miller Wolman D, Greenfield S, Steinberg E, eds. Institute of Medicine Committee on standards for developing trustworthy clinical practice G. Clinical Practice Guidelines We Can Trust. National Academies Press (US); 2011.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- MedlinePlus Health Information

[1] Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966-984.

[2] Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966-984.

[3] Ohanian M, Kantarjian HM, Shoukier M, et al. The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia. Am J Hematol. 2020;95:1127-1134.

[4] Ohanian M, Kantarjian HM, Shoukier M, et al. The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia. Am J Hematol. 2020;95:1127-1134.

[5] Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol. 2004;57(12):1288-1294.

[6] Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol. 2004;57(12):1288-1294.

[7] Mnatzaganian G, Davidson DC, Hiller JE, Ryan P. Propensity score matching and randomization. J Clin Epidemiol. 2015;68(7):760-768.

[8] Mnatzaganian G, Davidson DC, Hiller JE, Ryan P. Propensity score matching and randomization. J Clin Epidemiol. 2015;68(7):760-768.

[9] Graham R, Mancher M, Miller Wolman D, Greenfield S, Steinberg E, eds. Institute of Medicine Committee on standards for developing trustworthy clinical practice G. Clinical Practice Guidelines We Can Trust. National Academies Press (US); 2011.

[10] Graham R, Mancher M, Miller Wolman D, Greenfield S, Steinberg E, eds. Institute of Medicine Committee on standards for developing trustworthy clinical practice G. Clinical Practice Guidelines We Can Trust. National Academies Press (US); 2011.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase

Affiliations

Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase

Authors

Affiliations

Similar articles

References

REFERENCES

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Similar articles

References

REFERENCES

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical